Overview of Argenx’s Drug Pipeline | Therapeutic Areas | R&D Status
Argenx SE is a biopharmaceutical company that was founded in 2008 and is based in Zuid-Holland, Netherlands. The company focuses on the development of innovative antibody-based therapies for the treatment of various diseases. Argenx is a company based on Cameliaceae IgG1 antibody drugs, Argenx has three major platforms - SIMPLE Antibody, Fc engineering technology and ENHANZESC drug delivery technology. Among them, the SIMPLE Antibody platform is currently the only platform in the world for therapeutic antibody drug development based on the variable region of llama IgG1 antibody, aiming to actively immunize inbred camels with target antigens to provide antibodies that are almost identical to human antibodies in variable regions (V regions). In this report, we will analyze the distribution of therapeutic areas, the most frequently developed targets, and the pipeline of argenx SE.
👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of argenx.
The distribution of therapeutic areas
The company has a diverse portfolio of drugs targeting different therapeutic areas. The largest therapeutic area is immune system diseases, with a drug count of 8. This indicates that argenx SE has a strong focus on developing therapies for immune-related disorders. Other diseases, nervous system diseases, neoplasms, and skin and musculoskeletal diseases are also areas of interest for the company, with drug counts of 6, 5, 5, and 4, respectively. Hemic and lymphatic diseases, respiratory diseases, urogenital diseases, congenital disorders, mouth and tooth diseases, endocrinology and metabolic disease, and eye diseases have lower drug counts, ranging from 2 to 1.
The most frequently developed targets by Argenx SE
FcRn and c-Met are the most frequently targeted proteins, with a drug count of 2 each. FcRn is involved in the recycling of immunoglobulins and plays a crucial role in the immune system. c-Met is a receptor tyrosine kinase that is implicated in various cellular processes, including cell growth and survival. Other targets such as LAG3, MUSK, C2 + Complement system proteins, CD70, galectin-10, C2, IL-6, IL-22R, and APOC3 have a drug count of 1 each, indicating that argenx SE is exploring a wide range of targets for therapeutic intervention.
An overview of Argenx’s pipeline
The pipeline is categorized into different phases of drug development. Currently, there are no drugs in the discovery phase. However, the company has 5 drugs in the preclinical phase, indicating that they are actively conducting research and development activities. In the Phase 1 stage, there are 3 drugs, followed by 4 drugs in Phase 2. However, 2 drugs have received approval, indicating that argenx SE has successfully brought these therapies to market.
In summary, argenx is a biopharmaceutical company that focuses on the development of antibody-based therapies for various diseases. The company has a diverse portfolio of drugs targeting different therapeutic areas, with a strong emphasis on immune system diseases. FcRn and c-Met are the most frequently targeted proteins, indicating the company's interest in these specific targets. The pipeline of argenx SE shows a significant presence in the preclinical and early clinical stages, with a few drugs in Phase 1 and Phase 2. The company has successfully obtained approval for 2 drugs, demonstrating its ability to bring therapies to market. Overall, argenx SE is actively engaged in the development of innovative therapies and has a promising pipeline for future growth and success in the pharmaceutical industry.
